Annexon. has been granted a patent for anti-C1q antibody Fab fragments, detailing a method to inhibit synapse loss by administering these fragments to patients experiencing adverse synapse loss. The fragments consist of specific heavy and light chains as defined by their respective sequences. GlobalData’s report on Annexon gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Annexon, NSAID cancer drugs was a key innovation area identified from patents. Annexon's grant share as of June 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-c1q antibody fab fragments for inhibiting synapse loss
The patent US11999779B2 outlines a method for inhibiting synapse loss through the administration of an antibody Fab fragment that specifically binds to C1q. This method is particularly aimed at patients experiencing adverse synapse loss due to various neurodegenerative disorders, including Alzheimer's disease. The claims detail that the antibody Fab fragment consists of a heavy chain and a light chain, with specific sequences identified as SEQ ID NO:1 and SEQ ID NO:2. Additionally, the method may involve the administration of neural progenitors or neurogenesis enhancers, and it emphasizes the fragment's role in inhibiting complement activation, which is linked to synapse loss.
Further claims expand the application of this method to treat diseases associated with C1q-mediated activation of the classical complement pathway, which includes a range of neurodegenerative disorders characterized by synapse loss and pathological synaptic pruning. The patent also covers inflammatory and autoimmune diseases, listing numerous conditions such as diabetes, rheumatoid arthritis, and various eye diseases. The antibody Fab fragment is noted to have a dissociation constant (KD) for mouse C1q ranging from 1 pM to 200 pM and may be humanized to enhance its therapeutic potential. Overall, the patent presents a comprehensive approach to addressing synapse loss and related disorders through targeted immunotherapy.
To know more about GlobalData’s detailed insights on Annexon, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
